p*******r
发帖数: 83 | 1 U.S. FDA approves AbbVie all-oral hepatitis C treatment
Dec 19 (Reuters) - U.S. health regulators on Friday approved AbbVie's all-
oral treatment for hepatitis C, providing the first competition for Gilead
Sciences huge selling and expensive medicine for the liver-destroying virus.
The AbbVie regimen consists of four different anti-viral drugs to be taken
as three pills in the morning and one in the evening. The U.S. Food and Drug
Administration approved the regimen, which will be sold under the brand
name Viekira Pak, for patients with genotype 1 form of the virus, the most
common type of hepatitis C and the most difficult to treat.
Gilead's Sovaldi, which was approved a year ago, had been selling at the
rate of about $3 billion per quarter due to huge pent up demand. Sovaldi is
now combined with another Gilead drug and sold as Harvoni, which is taken as
one pill once a day for 12 weeks at a cost of about $94,500. Some patients
can take it for just eight weeks, which costs about $63,000.
The AbbVie regimen has demonstrated similarly impressive efficacy to Gilead'
s, with cure rates above 90 percent, and minimal negative side effects.
But Gilead, which has come under intense pressure from U.S. health insurers,
politicians and pharmacy benefit managers over the high cost of its
treatment, is widely expected to dominate the market, given its convenience
advantage of fewer pills and drugs, unless AbbVie undercuts Harvoni on
pricing. (Reporting by Bill Berkrot and Caroline Humer; Editing by Chizu
Nomiyama) | h****e
发帖数: 374 | 2 批是批了，但也没见怎么涨啊
：U.S. FDA approves AbbVie all-oral hepatitis C treatment
：Dec 19 (Reuters) - U.S. health regulators on Friday approved AbbVie's
all-
：oral treatment for hepatitis C, providing the first competition for Gilead
：Sciences huge selling and expensive medicine for the liver-destroying
virus.
：
：The AbbVie regimen consists of four different anti-viral drugs to be taken
：as three pills in the morning and one in the evening. The U.S. Food and
Drug Administration approved the regimen, which will be sold under the brand
……
【在 p*******r 的大作中提到】
: U.S. FDA approves AbbVie all-oral hepatitis C treatment
: Dec 19 (Reuters) - U.S. health regulators on Friday approved AbbVie's all-
: oral treatment for hepatitis C, providing the first competition for Gilead
: Sciences huge selling and expensive medicine for the liver-destroying virus.
: The AbbVie regimen consists of four different anti-viral drugs to be taken
: as three pills in the morning and one in the evening. The U.S. Food and Drug
: Administration approved the regimen, which will be sold under the brand
: name Viekira Pak, for patients with genotype 1 form of the virus, the most
: common type of hepatitis C and the most difficult to treat.
: Gilead's Sovaldi, which was approved a year ago, had been selling at the
| b*********h
发帖数: 240 | 3 因为价格不低，要83k for 12 weeks.
这下大家可以买 gilead 了。 | f******y
发帖数: 830 | 4 借这个帖发个言，八万三其实和gild差不多价，因为gild 二代药有40%的病人8个星期
就治好了，全疗程只有6万多。
我前天说可以买gild put，是判断abbv 会打价格战。结果大家都看到了。
今天和一个朋友讨论，他说我太天真了，药厂有默契的，不会相互压价，这样两家都会
被保险公司搞死。
我对看我帖赔钱的人道歉。
【在 b*********h 的大作中提到】
: 因为价格不低，要83k for 12 weeks.
: 这下大家可以买 gilead 了。
|
|
